There is clearly a huge market opportunity - mainly in the US Market. But, the company has demonstrated the execution and business model risk around contracting and business model revenue recognition. I believe they need to be more transparent around revenue - the reference to reporting ARR rather than ACV is a nod to this. If they can deliver new contract wins and show net dollar retention in excess of 100% due to increased utilization during FY24 the stock price is a no brainer growth opportunity, if not - it is basically dead due to cost concerns already laid out. For long time shareholders the original premise is still intact - but if FY24 is not a 'big year' in terms of growth the shareholder base will erode and speculators will manipulate the price around the left over carcass. dyor.
- Forums
- ASX - By Stock
- Ann: Preliminary Final Report
There is clearly a huge market opportunity - mainly in the US...
-
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add 3DP (ASX) to my watchlist
(20min delay)
|
|||||
Last
4.0¢ |
Change
-0.002(4.76%) |
Mkt cap ! $33.81M |
Open | High | Low | Value | Volume |
4.2¢ | 4.2¢ | 4.0¢ | $7.105K | 176.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 76771 | 4.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.1¢ | 1949372 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 76771 | 0.040 |
4 | 314050 | 0.039 |
5 | 190815 | 0.038 |
2 | 120000 | 0.037 |
3 | 300300 | 0.036 |
Price($) | Vol. | No. |
---|---|---|
0.041 | 1949372 | 2 |
0.042 | 15773 | 1 |
0.043 | 150000 | 1 |
0.044 | 100000 | 1 |
0.045 | 18000 | 1 |
Last trade - 11.15am 12/11/2024 (20 minute delay) ? |
Featured News
3DP (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online